After spinning off its consumer division into Kenvue in 2023, Johnson & Johnson (JNJ) focused on patented drugs in its Innovative Medicine pillar and devices and systems in its MedTech pillar.
With an upcoming separation of its orthopedics segment, will the firm’s focus continue to deliver stellar growth and an enhanced moat? Is it priced for perfection, creating risk for investors?
